Thermo Fisher Scientific reported strong Q2 results with adjusted EPS of $6.03 and nearly $12 billion in sales, surpassing analyst estimates. The company saw broad growth across all segments, including Life Sciences Solutions, Analytical Instruments, and Laboratory Products. A new partnership for cystic fibrosis treatment also boosted investor confidence, leading Jefferies to raise the price target to $630, suggesting a 10% upside. The stock rose 4.4% in pre-market trading following the announcement.
Argenx reported strong Q2 product net sales of $1.5 billion, a 60% increase year-over-year, driven by robust sales of its autoimmune treatment Vyvgart. RBC Capital raised its price target for Argenx stock to $1,025 from $945 and maintained an Outperf...
TotalEnergies reported strong financial results for Q2 2026, with earnings per share (EPS) of $2.68, slightly above analyst expectations of $2.66. The company’s revenue reached $57.10 billion, surpassing estimates of $55.13 billion, driven by higher ...
Verizon Communications is set to report its Q2 2026 earnings with analysts expecting an EPS of $1.27 and revenue around $35.16 to $35.31 billion. The company is undergoing major restructuring, including selling 274 stores and cutting over 13,000 jobs...
Tenet Healthcare Corporation's stock price targets have declined, reflecting analyst caution amid upcoming Q2 earnings. The company may experience pressure from lower patient days, but this could be offset by higher revenue per patient and growth in ...
Dorchester Minerals, L.P. announced a cash distribution of $1.272943 per common unit for the second quarter of 2026, payable on August 13, 2026. The distribution reflects cash receipts of about $50.4 million from royalty properties, $16.6 million fro...
